Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Artemether-lumefantrine dispersible tablet in infants and neonates <5 kg with P. falciparum malaria
NCT04300309Phase 3Terminated
- Sponsor
- Novartis
- Start
- Dec 2020
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of artemether + lumefantrine in Plasmodium falciparum malaria, sponsored by Novartis. Started Dec 2020; status: terminated.
02
Drugs
artemether + lumefantrine
03
Conditions
Plasmodium falciparum malaria
Beyond the preview
Go deeper on NCT04300309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04300309.